ARID1A is an inclusion criterion in 20 clinical trials for malignant solid tumor, of which 17 are open and 3 are closed. Of the trials that contain ARID1A status and malignant solid tumor as inclusion criteria, 10 are phase 1 (9 open), 5 are phase 1/phase 2 (3 open), and 5 are phase 2 (5 open) [4].

ARID1A is an inclusion criterion in 9 clinical trials for prostate adenocarcinoma, of which 8 are open and 1 is closed. Of the trials that contain ARID1A status and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 7 are phase 2 (6 open), and 1 is phase 3 (1 open) [4].

ARID1A is an inclusion criterion in 7 clinical trials for prostate carcinoma, of which 6 are open and 1 is closed. Of the trials that contain ARID1A status and prostate carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (3 open) [4].

ARID1A is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 3 are open and 2 are closed. Of the trials that contain ARID1A status and breast carcinoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 4 clinical trials for ovarian carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ARID1A status and ovarian carcinoma as inclusion criteria, 3 are phase 1 (3 open) and 1 is phase 1/phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 4 clinical trials for primary peritoneal carcinoma, of which 4 are open and 0 are closed. Of the trials that contain ARID1A status and primary peritoneal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for cervical carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A status and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for colorectal carcinoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A status and colorectal carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for endometrial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and endometrial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for endometrial endometrioid adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A status and endometrial endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for fallopian tube carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and fallopian tube carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 2 are open and 1 is closed. Of the trials that contain ARID1A status and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for ovarian clear cell adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for small cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and small cell lung carcinoma as inclusion criteria, 3 are phase 1/phase 2 (3 open) [4].

ARID1A is an inclusion criterion in 3 clinical trials for urothelial carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ARID1A status and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for malignant ovarian clear cell tumor, of which 1 is open and 1 is closed. Of the trials that contain ARID1A status and malignant ovarian clear cell tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for malignant ovarian epithelial tumor, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and malignant ovarian epithelial tumor as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for ovarian endometrioid adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and ovarian endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 0 are open and 2 are closed. Of the trials that contain ARID1A status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and cancer as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for cervical adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and cervical adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for cervical squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and cervical squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for endometrial clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and endometrial clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for epithelioid sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and epithelioid sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for esophageal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and esophageal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and esophageal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for fallopian tube clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and fallopian tube clear cell adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for high grade ovarian serous adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and high grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for malignant female reproductive system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and malignant female reproductive system neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for malignant ovarian endometrioid tumor, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and malignant ovarian endometrioid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for malignant soft tissue neoplasm, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and malignant soft tissue neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and ovarian carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for ovarian small cell carcinoma, hypercalcemic type, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and ovarian small cell carcinoma, hypercalcemic type as inclusion criteria, 1 is phase 1 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and peritoneal mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and pleural mesothelioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for primary peritoneal clear cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and primary peritoneal clear cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for renal pelvis urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and renal pelvis urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and rhabdoid tumor as inclusion criteria, 1 is phase 1 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for sarcomatoid carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and sarcomatoid carcinoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and synovial sarcoma as inclusion criteria, 1 is phase 1 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for ureter urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and ureter urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for urethral urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and urethral urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for uterine corpus carcinosarcoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and uterine corpus carcinosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for uveal melanoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and uveal melanoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

ARID1A is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ARID1A status and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].